X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

and welcome to X4 Pharmaceuticals Third Quarter Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Ferry, from LifeSci Advisors. Thank you, Mr. Ferry. You may begin. Thank you, Operator. And good morning, everyone. Presenting on today's call will be X4's Chief Executive Officer, Dr. Paula Regan, Chief Commercial Officer, Mark Baldry, and Chief Medical Officer, Dr. Krzysztof Arvet-Engels. Following prepared remarks by each, we will open up the call to your questions and will be joined by Chief Financial Officer, Adam Mostafa, Chief Scientific Officer, Art Tavares, and Chief Operating Officer, Mary DiBiase. As a reminder, on today's call, the company will be making forward-looking statements regarding regulatory and product development plans, as well as research activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Discretion of these risks can be found in X4's most recent filings with the SEC, including this quarter's Form 10-Q, which is expected to be filed after market close today. I'd now like to turn the call over to X4's President and CEO, Dr. Paula Regan. Paula? Thanks, Dan. Good morning, everyone, and thank you for joining us on the call today. To start, I'll be reviewing our third quarter events and recent highlights, the first two of which will be the primary focus of our discussion today. As you can see here, it's again been a very busy and productive period at X4, which culminated in the great news last week that our NDA, seeking approval of our lead drug candida...